Trials / Completed
CompletedNCT01077804
A Study to Evaluate Long-term Impact of VARIVAX Among Children and Adolescents (V210-036)(COMPLETED)
Fifteen Year Follow-up to Evaluate Long-term Effectiveness of VARIVAX Among Children and Adolescents
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 7,585 (actual)
- Sponsor
- Merck Sharp & Dohme LLC · Industry
- Sex
- All
- Age
- 12 Months – 23 Months
- Healthy volunteers
- Accepted
Summary
The purpose of these continuing post-licensure studies is to evaluate the long-term effectiveness of VARIVAX® \[Varicella Virus Vaccine Live (Oka/Merck)\] and to assess the impact of the vaccine on the epidemiology of varicella and herpes zoster.
Detailed description
Parents/guardians of the cohort of children vaccinated between 12 and 23 months of age during a six-month period in 1995 (June-November) at KPMCP Northern California were interviewed by telephone at 6-month intervals to ascertain whether their child had varicella or herpes zoster in the 6 months prior to interview. Follow-up continued for a minimum of 14 years after vaccination.
Conditions
Timeline
- Start date
- 1995-06-01
- Primary completion
- 2010-09-01
- Completion
- 2010-11-01
- First posted
- 2010-03-01
- Last updated
- 2017-09-15
- Results posted
- 2011-11-03
Source: ClinicalTrials.gov record NCT01077804. Inclusion in this directory is not an endorsement.